Abstract
Associations between HIV, antiretrovirals, and fat amount or repartition have a long history, like a television series with many seasons and episodes. The series began with the lipoatrophic effect of thymidine analogues (stavudine and zidovudine), then continued with truncal fat accumulation when thymidine analogues were withdrawn, without clearly ascertaining which antiretrovirals were involved into this fat gain.1 The discovery that HIV is present within fat reservoirs and involved into fat alterations was a novel episode,2 happening against the backdrop of a worldwide rising prevalence of obesity, affecting both the general population and people with HIV.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
